Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Basnett

MOHS-Micrographic Surgery Columbia, MO Medical Doctor

NPI 1013145234 CMS profile 4220207

401 N Keene St, Columbia, MO 65201

Open in the dashboard

General payments

$9,830

539 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Basnett of Columbia, MO is reported in the CMS Open Payments database as having received $9,830 across 539 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,418 75
2024 General $1,872 99
2023 General $1,906 104
2022 General $1,886 108
2021 General $1,564 88
2020 General $648 41
2019 General $537 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Basnett
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Andrew Basnett were reported at $1,418. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Andrew Basnett MOHS-Micrographic Surgery median Middle half National median
2019 $537 $316 $106–$785 $163
2020 $648 $162 $68–$412 $114
2021 $1,564 $243 $87–$654 $132
2022 $1,886 $300 $102–$887 $149
2023 $1,906 $364 $125–$1,010 $160
2024 $1,872 $445 $142–$1,108 $164
2025 $1,418 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,735 169 payments
  2. Novartis Pharmaceuticals Corporation $1,771 95 payments
  3. Janssen Biotech, Inc. $1,364 79 payments
  4. Lilly USA, LLC $474 31 payments
  5. Regeneron Healthcare Solutions, Inc. $388 21 payments
  6. Genzyme Corporation $322 10 payments
  7. LEO Pharma Inc. $235 12 payments
  8. Pfizer Inc. $228 13 payments
  9. Organogenesis Inc. $198 11 payments
  10. UCB, Inc. $195 10 payments
  11. Other $1,921 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,707 535 payments
  2. Education $123 4 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $1,389 78 payments
  2. TREMFYA $1,313 67 payments
  3. COSENTYX Dermatology $928 43 payments
  4. RINVOQ $897 58 payments
  5. COSENTYX Immunology $556 34 payments
  6. HUMIRA $475 32 payments
  7. TALTZ $458 30 payments
  8. DUPIXENT Immunology $432 14 payments
  9. OLUMIANT $266 17 payments
  10. DUPIXENT Inflammation And Immunology $225 13 payments
  11. Other $4,676 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

567

Median for Dermatology: 534

Drug cost

$11,403

Median for Dermatology: $67,151

Branded share of claims

3.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 88 $4,172
Ketoconazole Generic 115 $1,580
Triamcinolone Acetonide Generic 93 $1,271
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 21 $1,075
Tacrolimus Generic 15 $1,015
Mupirocin Generic 98 $673
Doxycycline Monohydrate Generic 14 $363
Fluocinolone Acetonide Generic 12 $360
Doxycycline Hyclate Generic 12 $263
Hydroxychloroquine Sulfate Generic 15 $249

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$817,953

Of which drugs: $39,637

Medicare patients

1,585

Average age 75

Services billed

11,402

704 women, 881 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 44%
Diabetes 25%
Ischemic heart disease 22%
Atrial fibrillation 17%
Chronic kidney disease 16%
Cancer 14%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Puraply xt, per square centimeter Q4197 Office 12 425 $37,980
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 22 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $389
$389 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $291
$291 — —
TREMFYA
  • Janssen Biotech, Inc. $242
$242 — —
DUPIXENT
  • GENZYME CORPORATION $92
  • Regeneron Healthcare Solutions, Inc. $67
$159 — —
RINVOQ
  • AbbVie, Inc. $145
$145 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

539 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record